New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
06:34 EDTMDT, HUMHumana claims Medtronic conspired with physicians, WSJ reports
Humana (HUM) is claiming that Medtronic (MDT) has violated the federal racketeering statute by conspiring with physicians to promote unapproved uses of its bone-growth drug, reports the Wall Street Journal. According to a lawsuit Humana filed in court last week, Medtronic may have paid $210M to prominent physicians to advocate for the drug's use in certain neck and spine surgeries. Reference Link
News For HUM;MDT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 10, 2016
07:35 EDTHUMHumana recorded premium deficiency reserve totaling $176M pretax in Q4
During 4Q 2015, the company recorded a premium deficiency reserve totaling $176 million pretax, or 74c per share, related to certain of its 2016 individual commercial policies.
07:34 EDTHUMHumana reports Q4 adjusted EPS $1.45, consensus $1.45
Subscribe for More Information
07:34 EDTHUMHumana sees 2016 projected net membership growth in standalone PDP 300K-330K
Subscribe for More Information
07:33 EDTHUMHumana sees Q1 adjusted EPS 'at least' $1.80, consensus $2.50
Subscribe for More Information
07:32 EDTHUMHumana sees FY16 adjusted EPS 'at least' $8.85, consensus $8.73
Subscribe for More Information
07:31 EDTHUMHumana reports Q4 EPS $1.45, consensus $1.45
Subscribe for More Information
February 9, 2016
14:36 EDTHUMNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Time Warner (TWX), consensus $1.01... Humana (HUM), consensus $1.45... Owens Corning (OC), consensus 45c... Carlyle Group (CG), consensus 31c... Medidata (MDSO), consensus 24c.
10:01 EDTMDTMedtronic: First patient treated with Valiant TAAA stent graft system in study
Subscribe for More Information
February 8, 2016
14:56 EDTMDTDexCom selloff overdone, based on misinformation, says Cowen
Subscribe for More Information
February 7, 2016
14:45 EDTHUMLeerink healthcare services analyst holds analyst/industry conference call
Subscribe for More Information
February 5, 2016
09:12 EDTMDTMedtronic reports results from retrospective analysis of iPro2 Professional CGM
Subscribe for More Information
08:05 EDTMDTMedtronic receives FDA approval for MRI CRT-D
Medtronic announced that it has received FDA approval for the first and only magnetic resonance imaging, or MRI, conditional cardiac resynchronization therapy defibrillators, or CRT-Ds, for the treatment of heart failure. The Medtronic Amplia MRI Quad CRT-D SureScan and Compia MRI Quad CRT-D SureScan systems are approved for MRI scans on any part of the body without positioning restrictions. Now, patients in the U.S. who receive these devices, which help treat their heart failure and reduce their risk of sudden cardiac arrest, have access to MRI scans if and when they need them. Both CRT-D systems will be commercially available in the coming months.
February 1, 2016
10:02 EDTMDTMedtronic announced CE Mark, commercial launch for Resolute Onyx expansion
Medtronic announced the recent CE Mark and commercial launch for an expanded size matrix of the Resolute Onyx DES, a next generation drug-eluting stent that is now available in 4.5mm and 5.0mm diameter sizes. The CE Mark also approved several new product indications including treatment of left main vessels and small vessels. Many coronary vessels are large in diameter of which a sub-set are left main, and now physicians can treat these large vessels with optimally sized stents that provide appropriate drug concentration. Resolute Onyx is the first DES available in these sizes among major manufacturers, offering the broadest size matrix to optimize the treatment of complex clinical scenarios. The Resolute Onyx DES is not commercially available in the United States.
08:05 EDTMDTMedtronic acquires Bellco
Medtronic announced it acquired privately-held Bellco, a pioneer in hemodialysis treatment solutions. Bellco's portfolio bolsters Medtronic's legacy renal access business and will be a foundational component of the company's recently formed Renal Care Solutions business. The Bellco transaction is expected to meet Medtronic's long-term financial metrics for acquisitions. Medtronic expects the net impact from the transaction to be earnings neutral in FY16 and neutral to accretive to earnings thereafter.
06:03 EDTHUMAetna on track to close Humana transaction in 2H16
The company commented, "We continue to work diligently with the Department of Justice and state regulators toward final approval of our proposed acquisition of Humana, and we continue to advance our integration readiness plans. We have obtained seven of the necessary state approvals, and we believe we remain on track to close the transaction in the second half of 2016."
January 29, 2016
16:25 EDTMDTMedtronic to present transcatheter pacing data to FDA
Subscribe for More Information
14:24 EDTHUMEarnings Watch: Aetna down 9% since last report
Aetna (AET) is scheduled to report fourth quarter earnings before the market open on Monday, February 1, with a conference call scheduled for 8:30 am ET. Aetna, a diversified health care benefits company in the United States, operates in three segments: Health Care, Group Insurance, and Large Case Pensions. EXPECTATIONS: Analysts are looking for earnings per share of $1.21 on revenue of $14.93B, according to First Call. The consensus range for EPS is $1.16-$1.32 on revenue of $14.44B-$15.36B. LAST QUARTER: Aetna reported third quarter EPS of $1.90 on revenue of $14.97B against analyst estimates of $1.77 and $14.95B, respectively. The company raised its fiscal 2015 EPS view to $7.45-$7.55 from "at least $7.40." Operating earnings were $668.6M for Q315 compared with $638.6M for Q314. The increase in operating earnings was primarily due to higher underwriting margins in Aetna's Health Care segment, partially offset by an increase in general and administrative expenses and lower underwriting margins in Aetna's Group Insurance segment. On January 11, Aetna said it see FY15 EPS at the high end of the $7.45-$7.55 range. Consensus for FY15 EPS is $7.54. STREET RESEARCH: On January 15, Wells Fargo said it expects health insurers' stock to do well this year, as the firm expects M&A deals made the last years to increase profits this year, and it thinks investors should be attracted to what it sees as the defensive names in the sector. Wells does not believe that any changes to or replacements of the ACA will be worse for the sector than the status quo. It identified Aetna and HCA Holdings (HCA) as its favorite names in the sector. On January 25, Leerink analyst Ana Gupte said she believed the recent selloff has provided a "strong" buying opportunity in the Managed Care space. Valuations are attractive on multiple metrics, Gupte told investors in a research note. Her top picks are UnitedHealth (UNH), Aetna, Humana (HUM) and Molina Healthcare (MOH). The analyst also favors Anthem (ANTM) and Cigna (CI). PRICE ACTION: Shares of Aetna are down approximately 9% since its last earnings report. The stock is up 2.6% to $101.42 in Friday afternoon trading ahead of Monday morning's report.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use